

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: RICCARDI, Carlo

Application No.: 09/403,861

Filed: February 11, 2000

For: INTRACELLULAR MODULATORS OF APOPTOTIC CELL DEATH PATHWAYS

Art Unit: 1635

Examiner: J. Epps

Washington, D.C.

Atty.'s Docket: RICCARDI=1

Date: December 3, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] Amendment []

in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 8	MINUS	** 20		0
INDEP.	* 1	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
\$	

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on .

Other Than Small Entity

Response Filed Within

[XX] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Please charge my Deposit Account No. 02-4035 in the amount of \$.

[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ 110.00.

[] A check in the amount of \$ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

12/04/2001 MGBREH1 00000045 09403861


01 FC:115


110.00 OP

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
Allen C. Yun
Registration No. 37,971



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1635
)	
RICCARDI, Carlo)	Examiner: J. Epps
)	
Appln. No.: 09/403,861)	Washington, D.C.
)	
Filed: February 11, 2000)	December 3, 2001
)	
For: INTRACELLULAR MODULATORS)	Atty. Docket: RICCARDI=1
OF APOPTOTIC CELL DEATH)	
PATHWAYS)	

Amendment

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of August 8, 2001,
petition and payment for a one month extension of time being
attached hereto, please amend as follows:

IN THE CLAIMS

Please cancel non-elected ☒ claims 1-10, 13, 14, 24,
and 27-40 without prejudice to the filing of a divisional
application(s) thereon.

///
Please cancel claims 11, 12, and 26 without prejudice
and add new claims 41-48 in place thereof as follows:

--41(New). A GIDR protein encoded by the nucleotide
sequence of SEQ ID NO:1 or by a nucleotide sequence capable of

EX
SUB
F1